Revvity
RVTY
$113.53
+7.48%
Revvity, Inc. is a global life sciences and diagnostics company, formed in 2023 following the rebranding of PerkinElmer, operating in the Medical - Diagnostics & Research industry. The company is a significant player in two core segments: Life Sciences, providing reagents, instruments, and software for biopharma and academic research, and Diagnostics, offering tools for immunodiagnostics and newborn and reproductive health. The current investor narrative is focused on the company's post-rebranding execution, navigating a post-pandemic normalization in its diagnostics business while seeking growth in its life sciences segment, with recent financials showing modest revenue growth but significant margin pressure compared to prior periods, indicating a transition phase for the business.…
RVTY
Revvity
$113.53
Investment Opinion: Should I buy RVTY Today?
Rating: Hold. The core thesis is that RVTY is a transition story with an attractive forward valuation but substantial near-term execution risk, making it prudent to wait for evidence of margin stabilization before committing capital. This aligns with the mixed institutional sentiment, which shows an even split between Buy and Hold ratings.
The Hold rating is supported by four key data points: 1) The forward P/E of 17.2x is reasonable if the $7.22 EPS materializes, 2) TTM Free Cash Flow of $510.8 million provides a financial safety net, 3) Revenue is still growing at a modest 5.85% YoY pace, and 4) The stock has shown technical resilience, rebounding 16.36% in 3 months from deeply oversold conditions. However, these positives are counterbalanced by the alarming Q4 gross margin of 43.8% and the high trailing P/E of 45.5x.
The two biggest risks are persistent margin pressure and a failure to hit forward EPS estimates. This Hold would upgrade to a Buy if the company demonstrates a clear recovery in gross margins above 47% in the next quarter or if the stock price retreats to the low-$90s, offering a larger margin of safety. It would downgrade to a Sell if margins deteriorate further below 42% or if revenue growth turns negative. Relative to its own volatile history and given the current mixed signals, the stock appears fairly valued, trading between the hope of a recovery and the reality of recent profit compression.
Sign up to view all
RVTY 12-Month Price Forecast
The investment case for RVTY is balanced on a knife's edge between a promising forward valuation and demonstrable near-term fundamental deterioration. The market is giving the company credit for a significant earnings recovery (forward P/E 17.2x), but the recent gross margin collapse raises serious doubts about achievability. The strong free cash flow and solid balance sheet provide a floor, but the high trailing P/E and volatility limit upside. The stance is neutral with medium confidence due to this conflict. An upgrade to bullish would require consecutive quarters of margin improvement and revenue acceleration. A downgrade to bearish would be triggered by a further decline in profitability or a guidance reduction that shatters the forward earnings narrative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Revvity's 12-month outlook, with a consensus price target around $147.59 and implied upside of +30.0% versus the current price.
Average Target
$147.59
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$91 - $148
Analyst target range
Analyst coverage for RVTY is limited, with only 3 analysts providing estimates, which is low for a company of its market cap and suggests it may be under-followed by the broader institutional community, potentially leading to higher volatility and less efficient price discovery. The analyst estimates focus on future financials, with an average EPS estimate of $7.22 (range $7.16 to $7.43) and average revenue estimate of $3.53 billion for the period ahead, but a consensus price target and explicit buy/hold/sell distribution are not provided in the data, preventing a calculation of implied upside or downside; the available institutional ratings show a mix of opinions, including Outperform/Overweight/Buy from Barclays, TD Cowen, and Evercore ISI, and Hold/Neutral/Equal Weight from Jefferies, JP Morgan, and Wells Fargo, indicating a balanced but not overwhelmingly bullish sentiment among those who do cover the stock.
Bulls vs Bears: RVTY Investment Factors
The bull case for RVTY hinges on a successful transition and a materializing earnings recovery, as evidenced by the attractive forward P/E of 17.2x and strong free cash flow. The bear case highlights severe and recent margin compression and an expensive trailing valuation that demands flawless execution. Currently, the bear side presents stronger evidence due to the concrete, sharp deterioration in profitability metrics in the latest quarter. The single most important tension in the investment debate is whether the company can stabilize and expand its gross margins back towards historical levels (53%) while delivering on the analyst-forecasted EPS of $7.22. The resolution of this margin pressure will determine if the forward earnings multiple is justified or merely hopeful.
Bullish
- Strong Forward P/E Implies Earnings Recovery: The forward P/E of 17.2x is significantly lower than the trailing P/E of 45.5x, indicating the market expects a substantial earnings rebound. This is supported by analyst consensus EPS estimates of $7.22, which would represent a dramatic improvement from the trailing EPS of $0.022.
- Robust Free Cash Flow Generation: The company generates strong free cash flow, with TTM FCF of $510.8 million, translating to a healthy FCF yield of approximately 4.6%. This provides financial flexibility for investments, debt repayment, and shareholder returns, underpinning a solid balance sheet with a manageable debt-to-equity ratio of 0.485.
- Technical Recovery from Oversold Levels: The stock has rebounded 16.36% over the last 3 months, outperforming the SPY's 15.14% gain, and is trading at 84.5% of its 52-week range. This suggests the downtrend from the 52-week high may be reversing, with the $81.22 low acting as a firm support level.
- Positive Revenue Growth Amid Transition: Q4 2025 revenue grew 5.85% year-over-year to $772.1 million. While sequential quarterly revenue is volatile, the positive YoY growth indicates the company is navigating post-pandemic normalization and executing its rebranding strategy.
Bearish
- Severe Margin Compression in Recent Quarter: Q4 2025 gross margin collapsed to 43.80%, a stark decline from the TTM gross margin of 53.08%. This 9.28 percentage point drop signals significant cost or pricing pressure, directly impacting profitability as the net margin also fell to 12.74% from 13.03% a year prior.
- Elevated Trailing P/E and High Volatility: A trailing P/E of 45.5x is high for a healthcare tools company, suggesting the stock is expensive based on current earnings. Combined with a beta of 1.107 and a 30.14% max drawdown, this indicates high volatility and valuation risk if the expected earnings recovery falters.
- Limited Analyst Coverage and Underperformance: With only 3 analysts providing estimates, RVTY is under-followed, which can lead to inefficient price discovery and higher volatility. The stock's 1-year return of 5.92% significantly underperforms the SPY's 24.99%, reflecting weak relative strength and investor skepticism.
- Inconsistent Quarterly Revenue Trajectory: Revenue from Q1 to Q4 2025 shows a volatile pattern ($664.8M, $720.3M, $698.9M, $772.1M) rather than a steady climb. This inconsistency suggests underlying demand is lumpy and challenges the narrative of a smooth post-rebranding growth acceleration.
RVTY Technical Analysis
The prevailing price trend for RVTY is one of significant volatility within a downtrend, with the stock down 30.14% from its 52-week high and posting a modest 1-year price change of 5.92%, significantly underperforming the SPY's 24.99% gain. Currently trading at a price of $100, it sits at approximately 84.5% of its 52-week range ($81.22 to $118.3), indicating it is recovering from lows but remains well off its peak, suggesting the stock is in a recovery phase from deeply oversold conditions rather than exhibiting strong momentum. Recent short-term momentum shows a divergence, with a strong 3-month gain of 16.36% outpacing the SPY's 15.14% rise, yet a more muted 1-month gain of 4.31% that still beats the market's 0.74%, signaling that while a recovery is underway, the pace of the rebound may be decelerating as it approaches technical resistance. Key technical levels are clearly defined by the 52-week low of $81.22, which now acts as major support, and the 52-week high of $118.30, representing substantial overhead resistance; a sustained breakout above $118.30 would signal a full reversal of the downtrend, while a breakdown below $81.22 would indicate a resumption of the bear market, with the stock's beta of 1.107 indicating it is roughly 11% more volatile than the broader market, which is a moderate risk factor for investors.
Beta
1.11
1.11x market volatility
Max Drawdown
-30.1%
Largest decline past year
52-Week Range
$81-$118
Price range past year
Annual Return
+16.2%
Cumulative gain past year
| Period | RVTY Return | S&P 500 |
|---|---|---|
| 1m | +17.2% | -2.2% |
| 3m | +35.3% | +15.8% |
| 6m | +17.3% | +6.4% |
| 1y | +16.2% | +20.9% |
| ytd | +15.7% | +7.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RVTY Fundamental Analysis
Revenue growth is modest but positive, with Q4 2025 revenue of $772.1 million representing a 5.85% year-over-year increase; however, examining the quarterly sequence from Q1 2025 ($664.8M) to Q4 2025 ($772.1M) shows revenue has been sequentially volatile, not demonstrating a clear, steady acceleration, which suggests underlying demand is inconsistent. The company is profitable with a Q4 2025 net income of $98.4 million, but profitability metrics reveal pressure, as the net margin of 12.74% in that quarter is down from 13.03% in Q4 2024, and the gross margin of 43.80% is significantly lower than the 53.08% trailing twelve-month figure, indicating recent cost or pricing pressures are compressing profitability. The balance sheet and cash flow position is solid, with a strong current ratio of 1.68, a manageable debt-to-equity ratio of 0.485, and robust trailing twelve-month free cash flow of $510.8 million, yielding a healthy FCF yield of approximately 4.6% based on the market cap, indicating the company generates sufficient cash to fund operations, return capital, and invest without over-reliance on external financing.
Quarterly Revenue
$772056000.0B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.43%
Latest Quarter
Free Cash Flow
$510810000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RVTY Overvalued?
Given a positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is elevated at 45.49x, while the forward P/E is substantially lower at 17.18x; this wide gap implies the market is pricing in a significant recovery in earnings, with forward estimates anticipating nearly a tripling of EPS from the trailing $0.022 to an estimated $7.22. Compared to sector averages (data not available in the provided set), a precise peer comparison cannot be quantified, but a trailing P/E of 45.5x is generally high for a healthcare tools company unless growth expectations are exceptional, while the forward P/E of 17.2x appears more reasonable if the earnings recovery materializes. Historically, the stock's own trailing P/E has fluctuated wildly, from a low near 7.3x in early 2023 to highs over 359x; the current 45.5x is above the median of its recent historical range but well below the extreme peaks, suggesting the market is pricing in improved fundamentals but not the euphoric levels seen during the pandemic, leaving room for multiple expansion if execution improves.
PE
46.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 7x~359x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on profitability and execution. The severe compression in Q4 gross margin from 53.08% (TTM) to 43.80% is a critical red flag, indicating either rising input costs, unfavorable product mix, or pricing pressure that could derail the earnings recovery priced into the forward P/E. While the balance sheet is solid with a 1.68 current ratio and manageable debt, the company's valuation (45.5x trailing P/E) is entirely dependent on achieving forecasted high earnings growth; any stumble would trigger significant multiple compression. Revenue concentration in the cyclical diagnostics segment, which is normalizing post-pandemic, adds to earnings volatility.
Market & Competitive Risks are elevated by valuation and sentiment. Trading at a trailing P/E of 45.5x, RVTY carries a high valuation compression risk if growth disappoints, especially given its beta of 1.107 makes it more volatile than the market. The stock is under-followed with only 3 analysts, leading to potential liquidity gaps and exaggerated price moves on news. Competitive pressures in both life sciences and diagnostics could prevent margin recovery, while a sector rotation away from healthcare or rising interest rates could further pressure its premium multiple.
Worst-Case Scenario involves a failure to arrest margin decline combined with a broader market downturn. If Q4's gross margin of 43.8% becomes the new norm and revenue growth stalls, the projected EPS of $7.22 would be at risk, leading to analyst downgrades and a derating of the forward multiple. A re-test of the 52-week low of $81.22 is plausible, representing a downside of approximately -19% from the current price near $100. In a severe bear case where the company misses estimates and the market sours on its story, the stock could fall toward the $75-$80 range, implying a potential loss of 20-25% for investors.
FAQ
The key risks, in order of severity, are: 1) Profitability Risk: The drastic Q4 gross margin drop from 53.1% to 43.8% may persist, crushing earnings forecasts. 2) Execution/Rebranding Risk: The company may fail to successfully grow its Life Sciences segment to offset post-pandemic diagnostics normalization. 3) Valuation & Volatility Risk: The high trailing P/E and beta of 1.107 make the stock prone to sharp declines if growth disappoints. 4) Sentiment/Liquidity Risk: Limited analyst coverage (only 3) can lead to exaggerated price moves and inefficient discovery.
The 12-month forecast is bifurcated, with a 50% probability base case target range of $100-$115, a 30% probability bull case target of $118-$130, and a 20% probability bear case target of $81-$95. The base case, which is most likely, assumes the company stabilizes its margins and delivers EPS near the lower end of the $7.22 consensus, resulting in modest upside from current levels. The key assumption is that the severe margin compression witnessed in Q4 2025 is not a new normal but a transient issue. The forecast hinges entirely on the company's ability to prove this in upcoming quarters.
RVTY's valuation sends mixed signals. Based on trailing earnings (P/E of 45.5x), the stock appears overvalued for a healthcare tools company. However, based on forward analyst estimates (forward P/E of 17.2x), it appears reasonably valued or even slightly undervalued if growth materializes. This wide gap indicates the market is paying a premium for expected future growth, not current performance. The valuation implies the market expects a near-tripling of EPS. Therefore, it is fairly valued only if the aggressive earnings recovery forecast proves accurate; otherwise, it is overvalued.
RVTY presents a high-risk, high-reward opportunity that is not a clear-cut 'good buy' for all investors. For those with a higher risk tolerance and a belief in the company's turnaround, the forward P/E of 17.2x offers reasonable value if the projected $7.22 EPS is achieved. However, the severe recent margin compression and high stock volatility (beta 1.107) pose significant risks. It could be a good buy for speculative capital waiting for a margin recovery catalyst, but it is not suitable for a core, low-risk portfolio holding given the current execution uncertainties.
RVTY is more suitable for a medium- to long-term investment horizon (minimum 12-18 months) rather than short-term trading. The investment thesis is based on a corporate turnaround and earnings recovery story that will take multiple quarters to validate or invalidate. The stock's high volatility (beta 1.107) and lack of a meaningful dividend (yield 0.3%) make it poor for short-term income or low-risk trading. Investors should be prepared to hold through volatility to see if the forward earnings potential is realized. A concrete holding period of at least through the next two earnings cycles is recommended to assess the margin trajectory.